KEITH LANIER BLACK
Medical Practice in Los Angeles, CA
License number
Michigan 4301045111
Issued Date
Aug 16, 1982
Expiration Date
Jan 31, 2019
Category
Medicine
Type
Medical Doctor
Address
Address
Los Angeles, CA 90048
Professional information
Creative Producer Nfl All Morning Nfl Network
Position:
Creative Producer at National Football League (NFL AM)
Location:
Greater Los Angeles Area
Industry:
Entertainment
Work:
National Football League (NFL AM)
- Culver City since Jun 2012
-
Creative Producer
Red Car
- Culver City, CA Mar 2012 - Jun 2012
-
Project Manager
CBS Television Studios (Entertainment Tonight/The Insider)
- Studio City Aug 2010 - Mar 2012
-
Production/Directors Assistant
Twin Brother Productions
- Greater Los Angeles Area Aug 2010 - Mar 2012
-
Assistant Director
KFMB
- Greater San Diego Area Jan 2010 - Jan 2011
-
Promotions
iATN
- Orange County, California Area Nov 2005 - Jan 2011
-
Social Network Moderator/Support
CBS Television Studios (Entertainment Tonight)
- Studio City 2010 - 2010
-
Pre/Post Production Intern
Education:
San Diego State University-California State University 2007 - 2010
Bachelor of Business Administration (B.B.A.), Business Administration and Management, General Imperial College London 2009 - 2009
International Studies
Bachelor of Business Administration (B.B.A.), Business Administration and Management, General Imperial College London 2009 - 2009
International Studies
Interests:
Film, Television, and Animated Short Screenwriting. Comedy Sketch Writing and Performance. Improvisation. Producing, Story Boarding and Editing.
Languages:
Spanish
Use Of Sildenafil, Vardenafil And Other 5-Phosphodiesterase Inhibitors To Enhance Permeability Of The Abnormal Blood-Brain Barrier
US Patent:
2008018, Aug 7, 2008
Filed:
Feb 22, 2006
Appl. No.:
11/813494
Inventors:
Keith L. Black - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61K 31/4985, A61K 31/519, A61P 7/00
US Classification:
514250, 5142621
Abstract:
This invention relates to compositions, methods and kits for enhancing the permeability of the blood-brain barrier. Particularly, compositions comprising 5-phosphodiesterase inhibitors, such as sildenafil, vardenafil, or tadalafil, when administered to a mammal, will selectively enhance the permeability of the blood-brain barrier in abnormal brain tissue. This selective enhancement allows for selective delivery of therapeutic agents to treat the abnormal brain tissue; for example, a brain tumor.
Method For Using Potassium Channel Agonists For Delivering A Medicant To An Abnormal Brain Region And/Or A Malignant Tumor
US Patent:
7018979, Mar 28, 2006
Filed:
Jan 26, 2000
Appl. No.:
09/491500
Inventors:
Keith L. Black - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
A01N 61/00, A01N 37/18, A61K 31/00, A61K 38/00
US Classification:
514 1, 514 2
Abstract:
Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel agonist (other than bradykinin or a bradykinin analog), such as NS-1619,1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levcromakalim, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel agonist together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.
Polymalic Acid-Based Multifunctional Drug Delivery System
US Patent:
8562964, Oct 22, 2013
Filed:
Apr 29, 2011
Appl. No.:
13/097364
Inventors:
Julia Y. Ljubimova - Studio City CA, US
Keith Black - Los Angeles CA, US
Eggehard Holler - Los Angeles CA, US
Keith Black - Los Angeles CA, US
Eggehard Holler - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
Arrogene Nanotechnology, Inc. - Los Angeles CA
Arrogene Nanotechnology, Inc. - Los Angeles CA
International Classification:
A61K 47/48, A61P 35/00, C08F 8/30
US Classification:
424 7817, 525 541, 525 542
Abstract:
A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions.
Drug Delivery Of Temozolomide For Systemic Based Treatment Of Cancer
US Patent:
2012032, Dec 27, 2012
Filed:
Dec 10, 2010
Appl. No.:
13/513145
Inventors:
Rameshwar Patil - Los Angeles CA, US
Eggehard Holler - Los Angeles CA, US
Keith L. Black - Los Angeles CA, US
Julia Y. Ljubimova - Studio City CA, US
Eggehard Holler - Los Angeles CA, US
Keith L. Black - Los Angeles CA, US
Julia Y. Ljubimova - Studio City CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61K 47/48, C08G 63/91, A61P 31/00
US Classification:
424 7817, 525 541, 525419
Abstract:
The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.
Herpes Simplex Virus Type 1 (Hsv-1)-Derived Vector For Selectively Inhibiting Malignant Cells And For Expressing Desired Traits In Malignant And Non-Malignant Mammalian Cells
US Patent:
6838279, Jan 4, 2005
Filed:
Oct 29, 2001
Appl. No.:
10/046491
Inventors:
Steven L. Wechsler - Westlake Village CA, US
Anthony B. Nesburn - Malibu CA, US
John S. Yu - Los Angeles CA, US
Keith L. Black - Los Angeles CA, US
Anthony B. Nesburn - Malibu CA, US
John S. Yu - Los Angeles CA, US
Keith L. Black - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
A61K 4800, C12N 1563, C12N 1587, C12N 500
US Classification:
4353201, 435325, 435455, 435456, 435 691, 514 44, 4241991
Abstract:
Disclosed is an HSV-1-derived vector containing a DNA having a functional LAT promoter, or operative fragment thereof, a deletion in both copies of the HSV-1 LAT gene, and a deletion in both copies of the HSV-1 ICP34. 5 gene. The HSV-1-derived vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid encoding a preselected protein. In some embodiments, the preselected protein is a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-γ. Also, disclosed are kits for expressing in a mammalian cell a gene encoding a preselected protein, and mammalian cells containing the HSV-derived vectors.
Use Of 5-Phosphodiesterase Inhibitors To Enhance The Permeability Of The Blood-Brain Barrier Of Abnormal Brain Tissue And The Blood-Tumor Barrier
US Patent:
2009004, Feb 19, 2009
Filed:
Sep 26, 2008
Appl. No.:
12/238872
Inventors:
Keith L. Black - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61K 38/08, A61K 31/519, A61K 31/4985, A61P 35/00, A61K 31/282
US Classification:
514 15, 51425216, 514250, 514 34, 514492
Abstract:
This invention relates to methods and kits for enhancing the permeability of the blood-brain barrier of abnormal brain tissue or the blood-tumor barrier. Particularly, methods comprising the administration of 5-phosphodiesterase inhibitors, such as sildenafil and vardenafil, to selectively enhance the permeability of the blood-brain barrier of abnormal brain tissue or the blood-tumor barrier are described. This selective enhancement allows for selective delivery of therapeutic agents or imaging to treat the abnormal brain tissue or a tumor, including brain tumors and non-central nervous system tumors.
Polymalic Acid Based Nanoconjugates For Imaging
US Patent:
2012025, Oct 11, 2012
Filed:
Apr 6, 2012
Appl. No.:
13/441599
Inventors:
Keith L. Black - Los Angeles CA, US
Julia Ljubimova - Studio City CA, US
Alexander Ljubimov - Studio City CA, US
Eggehard Holler - Los Angeles CA, US
Julia Ljubimova - Studio City CA, US
Alexander Ljubimov - Studio City CA, US
Eggehard Holler - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61B 5/055, C08G 63/91
US Classification:
424 934, 525 541
Abstract:
Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.
Using Overexpression Of Laminin Alpha 4 Subunit As A Diagnostic And Prognostic Indicator Of Malignant Tumors
US Patent:
2002015, Oct 24, 2002
Filed:
Dec 19, 2000
Appl. No.:
09/741550
Inventors:
Julia Ljubimova - Studio City CA, US
Alexander Ljubimov - Studio City CA, US
Keith Black - Los Angeles CA, US
Alexander Ljubimov - Studio City CA, US
Keith Black - Los Angeles CA, US
International Classification:
C12Q001/68, G01N033/574
US Classification:
435/006000, 435/007230
Abstract:
Disclosed is a method of diagnosing the presence of a malignant tumor, including a glioma, in a human subject, which involves detecting overexpression of laminin 4 subunit protein or laminin 4-specific MRNA, compared to the expression level in a normal tissue control. Also disclosed are a method of predicting the recurrence of a malignant tumor in a human subject from whom a malignant tumor has been resected and a method of classifying the grade of a malignant tumor, such as a glial tumor, based on a molecular classification.
Cancer Vaccines And Vaccination Methods
US Patent:
2008031, Dec 18, 2008
Filed:
Sep 28, 2007
Appl. No.:
11/863990
Inventors:
John S. YU - Los Angeles CA, US
Gentao LIU - Los Angeles CA, US
Keith L. BLACK - Los Angeles CA, US
Gentao LIU - Los Angeles CA, US
Keith L. BLACK - Los Angeles CA, US
International Classification:
A61K 39/00, A61P 31/00
US Classification:
4241851, 4242771
Abstract:
Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.